S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:BNR

Burning Rock Biotech - BNR Stock Forecast, Price & News

$3.51
+0.16 (+4.78%)
(As of 08/5/2022 08:48 PM ET)
Add
Compare
Today's Range
$3.17
$3.56
50-Day Range
$1.75
$3.60
52-Week Range
$1.74
$24.06
Volume
268,100 shs
Average Volume
509,035 shs
Market Capitalization
$368.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Burning Rock Biotech MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.29mentions of Burning Rock Biotech in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.46) to ($1.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.19 out of 5 stars

Business Services Sector

391st out of 429 stocks

Medical Laboratories Industry

30th out of 30 stocks

BNR stock logo

About Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.

Burning Rock Biotech Trading Up 4.8 %

Shares of NASDAQ:BNR traded up $0.16 during trading hours on Friday, reaching $3.51. The stock had a trading volume of 268,112 shares, compared to its average volume of 386,466. The firm has a market cap of $368.94 million, a price-to-earnings ratio of -2.66 and a beta of -0.37. The business's fifty day moving average price is $2.74 and its two-hundred day moving average price is $5.68. Burning Rock Biotech has a 52-week low of $1.74 and a 52-week high of $24.06.

Burning Rock Biotech (NASDAQ:BNR - Get Rating) last announced its quarterly earnings results on Tuesday, May 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.16). The firm had revenue of $21.38 million during the quarter, compared to analysts' expectations of $19.99 million. Burning Rock Biotech had a negative net margin of 165.32% and a negative return on equity of 45.94%. During the same quarter in the previous year, the firm posted ($0.25) EPS. Equities research analysts anticipate that Burning Rock Biotech will post -1.46 earnings per share for the current fiscal year.

Receive BNR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter.

BNR Stock News Headlines

See More Headlines
Receive BNR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter.

BNR Company Calendar

Last Earnings
5/31/2022
Today
8/08/2022
Next Earnings (Confirmed)
8/31/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:BNR
Fax
N/A
Employees
1,394
Year Founded
N/A

Profitability

Net Income
$-125,020,000.00
Net Margins
-165.32%
Pretax Margin
-166.88%

Debt

Sales & Book Value

Annual Sales
$79.69 million
Book Value
$2.75 per share

Miscellaneous

Free Float
N/A
Market Cap
$368.93 million
Optionable
Not Optionable
Beta
-0.37














BNR Stock - Frequently Asked Questions

Should I buy or sell Burning Rock Biotech stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Burning Rock Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Burning Rock Biotech stock.
View analyst ratings for Burning Rock Biotech
or view top-rated stocks.

How has Burning Rock Biotech's stock price performed in 2022?

Burning Rock Biotech's stock was trading at $9.53 on January 1st, 2022. Since then, BNR shares have decreased by 63.2% and is now trading at $3.51.
View the best growth stocks for 2022 here
.

Are investors shorting Burning Rock Biotech?

Burning Rock Biotech saw a increase in short interest in July. As of July 15th, there was short interest totaling 909,700 shares, an increase of 70.9% from the June 30th total of 532,200 shares. Based on an average daily trading volume, of 823,100 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.1% of the shares of the company are short sold.
View Burning Rock Biotech's Short Interest
.

When is Burning Rock Biotech's next earnings date?

Burning Rock Biotech is scheduled to release its next quarterly earnings announcement on Wednesday, August 31st 2022.
View our earnings forecast for Burning Rock Biotech
.

How can I listen to Burning Rock Biotech's earnings call?

Burning Rock Biotech will be holding an earnings conference call on Wednesday, August 31st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Burning Rock Biotech's earnings last quarter?

Burning Rock Biotech Limited (NASDAQ:BNR) posted its quarterly earnings data on Tuesday, May, 31st. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.16. The firm had revenue of $21.38 million for the quarter, compared to analysts' expectations of $19.99 million. Burning Rock Biotech had a negative net margin of 165.32% and a negative trailing twelve-month return on equity of 45.94%. During the same quarter last year, the firm posted ($0.25) EPS.

What guidance has Burning Rock Biotech issued on next quarter's earnings?

Burning Rock Biotech updated its FY 2022 earnings guidance on Tuesday, June, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $97.80 million-$97.80 million, compared to the consensus revenue estimate of $92.48 million.

What other stocks do shareholders of Burning Rock Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA), Teck Resources (TECK), Herman Miller (MLHR) and Immunic (IMUX).

When did Burning Rock Biotech IPO?

(BNR) raised $196 million in an initial public offering on Friday, June 12th 2020. The company issued 13,500,000 shares at a price of $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

What is Burning Rock Biotech's stock symbol?

Burning Rock Biotech trades on the NASDAQ under the ticker symbol "BNR."

Who are Burning Rock Biotech's major shareholders?

Burning Rock Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (1.69%), Sumitomo Mitsui Trust Holdings Inc. (0.72%), Nikko Asset Management Americas Inc. (0.72%) and Assenagon Asset Management S.A. (0.42%).

How do I buy shares of Burning Rock Biotech?

Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Burning Rock Biotech's stock price today?

One share of BNR stock can currently be purchased for approximately $3.51.

How much money does Burning Rock Biotech make?

Burning Rock Biotech (NASDAQ:BNR) has a market capitalization of $368.93 million and generates $79.69 million in revenue each year. The company earns $-125,020,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does Burning Rock Biotech have?

Burning Rock Biotech employs 1,394 workers across the globe.

How can I contact Burning Rock Biotech?

Burning Rock Biotech's mailing address is 601 BUILDING 3 STANDARD INDUSTRIAL UNIT2, GUANGZHOU F4, 510005. The official website for Burning Rock Biotech is www.brbiotech.com. The company can be reached via phone at 86-185-0164-1666.

This page (NASDAQ:BNR) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.